EN 
PT Aché
A better living for you
Who we are
GRI 2-1 | 2-2
Aché has been working for 56 years in the development of innovative solutions, which result in differentiated products and services that are made available to the pharmaceutical market, with the purpose of bringing a better life to people, wherever they are.
We are one of the five largest pharmaceutical corporations in Brazil, according to the Pharmacy Purchase Price (PPP) methodology. We have one of the largest commercial and demand sales forces in the country, which provides a broad reach for promoting products, sharing scientific knowledge with health professionals, and offering the final consumer a complete portfolio with proven quality and safety.
We serve a total of 152 therapeutic classes and 21 medical specialties from our five industrial plants located in São Paulo (Capital), Guarulhos (SP), Londrina (PR), Anápolis (GO) and Cabo de Santo Agostinho (PE).
In 2022, we entered into important partnerships with the signing of 11 new licensing agreements, which should contribute to strengthening Aché’s pipeline with high-potential products.
Some of the products from our partnership agreements reached the market in 2022, among which we would particularly draw attention to the following:
• Edistride (dapagliflozina):in partnership with a company that enabled Aché to be the first Brazilian company to enter the market in the SGLT-2 class of oral antidiabetics
• Volare (enoxaparina):in partnership with a company to launch a biological product for outpatient and hospital use.
• Provance Mini (L. reuteri DSM 17938):a partnership with a company for extending our line of exclusive probiotics.
Aché products have reached new markets through licensing agreements, which makes it possible to serve 17 countries. The Company exports 32 products, especially Acheflan (anti-inflammatory), Lotar (treatment of hypertension) and Trezete (treatment of hypercholesterolemia).
Our Story
GRI 2-1 | 2-2
• Incorporation of Prodoctor
• Launch of the Acheflan,anti-inflammatory, the result of radical research, 100% developed in Brazil
• Expansion of internationalization, with a presence in 11 countries
• For the first time, winner of the Innovation Value Award
• Inauguration of the Molecular Design and Synthesis Laboratory
• Acquires Nortis Pharmaceutical,in Londrina (PR) and Tiaraju ChemicalPharmaceutical Laboratory
• Inauguration of the Nanotechnology Laboratory (NILE).
• Partnership with the National Center for Research in Energy and Materials (CNPEM) and Phytobios
• Inauguration of the InSPire Lab
• Creation of Innovatech Lab
• Inauguration of the Innovachem Lab
• Creation of Longevity Project
• Cultural evolution: Aché’s new way of being and doing
For the 8th consecutive year wins the Valor Inovação Award
1966
Aché founded by Adalmiro Dellape Baptista, Antônio Gilberto Depieri and Victor Siaulys
1973
New headquarters in Guarulhos
Incorporation of Prodoctor
1982
Aché starts marketing medicines of Parke-Davis
1990
Acquires 42% of Schering-Plough
2003
2005
Beginning in the generic market, with the a e acquisition of Biosintética.
Launch of the Acheflananti-inflammatory, the result of radical research, 100% developed in Brazil
2007
Entry into the dermocosmetics market
Expansion of internationalization with a presence in 11 countries
2009
Launch of the Care for Life Benefits program
2010
Acquires 50% of Melcon, manufacturing unit specializing in the production of hormonal drugs
2011
Launch of own line of dermocosmetics PROFUSE
2012
Participation in a joint venture with Bionovis,a biotechnology company
2015
Evolution of the brand’s purpose and positioning with the slogan: Aché. A Better Life For You
For the first time, winner of the Innovation Value Award
Inauguration of the Molecular Design and Synthesis Laboratory
2016
Aché turns 50 years
Acquires Nortis Pharmaceutical,in Londrina (PR) and Tiaraju ChemicalPharmaceutical Laboratory
2017
Launch of Achevita Line;
Inauguration of the Nanotechnology Laboratory (NILE).
Partnership with the National Center for Research in Energy and Materials (CNPEM) and Phytobios
2020
Strengthening the Company’s social role with the production and donation of hand sanitizer, drugs, PPE and food baskets
Inauguration of the InSPire Lab
2022
Launch of Prescription Biosynthetic Business Unit
Creation of Innovatech Lab
Inauguration of the Innovachem Lab
Creation of Longevity Project
Cultural evolution: Aché’s new way of being and doing
For the 8th consecutive year wins the Valor Inovação Award
Promoting Health
GRI 2-1 | 3-3
To promote people’s access to health and well-being, renewing Aché’s portfolio is an agile process, which also contributes to the growth and continuity of the Company
Investing BRL 276 million, 80% more than the previous year, Aché launched 43 products and made 373 brands available to the market in 980 presentations, in the segments of: prescription drugs; prescription-free drugs (MIP: Medicamentos Isentos de Prescrição); prescribed and prescription free generic drugs; dermocosmetics; nutricosmetics; cosmetics and food and hormonal supplements. With our objective of working in the promising area of biotechnology, since 2012 we have been part of a joint venture with Bionovis, a biotechnology company formed by Aché and three other Brazilian laboratories, which focuses on the production of biopharmaceuticals.
We have 266 projects in our pipeline in different stages of development, with a particular emphasis on eight projects based on Brazilian biodiversity. Our first launch is scheduled for 2026.
Main brands
How we generate value
GRI 2-6
FINANCIAL
» Net revenue of BRL 4.9 bi
» BRL 1.41 bi in EBITDA
MANUFACTURED
» BRL 197 m invested in operational excellence and in Phase II of the plant in Pernambuco
» BRL 28 m invested in quality
» 266 million units produced and installed capacity of 626 million in the five plants
» 313 million units distributed
SOCIAL AND RELATIONSHIP
» More than 21 million registered with the Care for Life Program
» More than 6.6 million medical contacts and 1.6 million contacts with POS
» BRL 8.6 m invested in social projects
» BRL 2.6 bi in contracts with suppliers
INTELLECTUAL
» BRL 276 m invested in innovation
NATURAL
» More than BRL 31 mi invested in environmental management
» 2.17 thousand tons of waste intended for recycling
» 223 million cartridges and 304 million leaflets made from reforestation wood
» Post-consumer medicine waste reverse logistics program
» 7,500 seedlings of native tree species of the Atlantic rain forest biome replanted in the Zumbi Forest
HUMAN
»More than BRL 982.7 m in value distributed in benefits and compensation to employees
» BRL 23.5 m invested in training
» More than 318 thousand hours of training given
Culture and commitments
GRI 2-6
We are Magenta
Our Way of Being and Doing, which is developed and driven by collaborative processes, establishes the culture and commitments that should be part of the daily lives of the entire Aché Generation. We believe that cultural evolution is key to achieving increasingly bold goals in a dynamic, complex, and highly competitive business environment.
Aché´s Way of Being and Doing clearly and objectively sets out the attitudes that should and should not be part of the way we operate and act. Commitments are made by each employee in the search to make possible the purpose that moves us: to bring a better life to people.
Our Way of Being
WE ARE PASSIONATE ABOUT LIFE
We work to promote health, healing and wellbeing. We take care of social issues, of nature and of our business in order to bring a better life to people
WE INNOVATE TO BE AHEAD ALWAYS
Our vision is to build a future that places us at the forefront of the pharmaceutical market. We work every day to discover what’s new and to offer effective and safe therapeutic solutions to benefit people’s health and well-being
WE TAKE CARE OF OUR CUSTOMERS
We establish lasting relationships that are guided by mutual learning and growth. We want to impact lives with our presence.
WE ARE INSPIRED BY TALENT AND DIVERSITY
Diversity is an important force that enables us to leverage talents and broaden worldviews. We believe in plurality to ensure business success.
WE CARE ABOUT OUR REPUTATION. IT IS NON-NEGOTIABLE
We are committed to acting with integrity and transparency in conducting our business, thus strengthening our reputation and ensuring the Company’s sustainability
Our Purpose
We bring relief for your pain,
Tranquility for your mind,
And beauty for your skin.
To the pharmaceutical market
We offer innovation,
To health professionals, information,
To our customers, solutions,
To the forest, trees,
To the community, inclusion,
To our employees, opportunities.
We offer society more culture,
education, and sport,
More treatment possibilities
for people,
And enhanced efficiency
for caregivers.
We have respect for the environment,
Offer a better future for the
generations to come,
And more well-being for the
entire family.
Our vocation is improving people’s
health and longevity,
And our mission is to offer
you a better life.